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Abstract
Pathologic complete response (pCR) is a common primary endpoint for a phase II trial or even accelerated approval
of neoadjuvant cancer therapy. If granted, a two-arm confirmatory trial is often required to demonstrate the efficacy
with a time-to-event outcome such as overall survival. However, the design of a subsequent phase III trial based on
prior information on the pCR effect is not straightforward.
Aiming at designing such phase III trials with overall survival as primary endpoint using pCR information from
previous trials, we consider a mixture model that incorporates both the survival and the binary endpoints. We propose
to base the comparison between arms on the difference of the restricted mean survival times, and show how the effect
size and sample size for overall survival rely on the probability of the binary response and the survival distribution
by response status, both for each treatment arm. Moreover, we provide the sample size calculation under different
scenarios and accompany them with an R package where all the computations have been implemented. We evaluate
our proposal with a simulation study, and illustrate its application through a neoadjuvant breast cancer trial.
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1. Introduction
Neoadjuvant therapy, hoping to shrink a tumor before surgery, has become increasingly common for early-stage
breast cancer. Examples of neoadjuvant therapy include chemotherapy, radiation therapy, and hormone therapy.
Neoadjuvant therapy permits breast conservation in patients who otherwise require mastectomy; enables direct evalu-
ation of the tumor response, which may add prognostic information; and allows for the examination of tissue, imaging,
and biomarkers from biopsy.[1]
In the context of early-stage breast cancer, the use of the binary endpoint pathologic complete response (pCR),
defined as the complete eradication of invasive cancer, has been proposed as an endpoint for accelerated approval by
regulatory agencies. Trials under accelerated pathways are allowed to base the benefit on surrogate or intermediate
endpoints. If granted, a confirmatory trial is still needed to demonstrate the efficacy based on long-term endpoints,
such as overall survival (OS) or event-free survival (EFS).[1, 2]
The association between pCR and survival endpoints has been extensively discussed in recent years. A meta-
analysis of existing randomized clinical trials and some cohort studies on neoadjuvant treatments showed that pCR
in non-metastatic HER2-positive patients was associated with longer times to recurrence or death.[3, 4, 5] However,
Cortazar et al[4] insightfully noted that higher pCR rates due to an intervention could not be used as a surrogate
endpoint for improved EFS and OS at the trial-level analyses; indeed, little association was observed between an
increased number of pCR responses and improved OS or EFS. Whereas at an individual patient level pCR endpoint
could be strongly associated with long-term EFS and OS endpoints,[5] this is not yet a proven correlation at the trial
level. How to predict a beneficial treatment effect on survival endpoints based on pCR improvement at trial level is
nontrivial.
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Several challenges arise when using pCR as a surrogate endpoint for a survival endpoint in the design of a phase
III trial. Hatzis et al[6] discuss how a large pCR treatment effect may not be translated into a similar long-term
survival effect at the trial level. The authors pointed out that modest or even large improvements in pCR rate may
only translate into small improvements in survival endpoints, particularly in a patient population with good long-term
prognoses. They evaluate, through simulation, the relationship between increased pCR rate and survival endpoints
with different baseline prognoses under two critical assumptions: (i) the survival distributions of patients with pCR
are the same, regardless which treatment was received; and (ii) the survival function of patients who do not achieve
pCR is also similar in both arms. These two assumptions imply that the survival benefit from the new therapy arm is
only derived from the improved pCR rate over the control arm. Whereas these assumptions could be reasonable for
triple-negative breast cancer under the two treatments of interest, this may not be the case for other trial settings, e.g.,
when the new therapy could reduce the extent of the disease even among non-pCR patients, thus improving long-term
survival endpoints compared to the control arm.
An imperative and practical question is: how can we use the short term efficacy results on pCR to design a phase III
trial with long-term survival endpoints? Based on historical data, we may have reasonable information on the survival
distributions among those who achieved pCR, and the survival distributions among those who do not for similar
patient populations. Motivated by such challenges, in this paper we aim to design a phase III trial for a two-sample
comparison between the control group and the intervention group, with respect to a long-term survival endpoint based
on previous information on a short-term binary endpoint and other available information.
Several authors have addressed how to compare two treatment groups in seamless phase II-III clinical trials with
binary and survival endpoints. While Inoue et al[7] proposed a Bayesian approach where the distribution of the
time-to-event outcome is specified through a mixture model according to the response, Lai et al[8] developed group
sequential tests for confirmatory testing based on likelihood ratio statistics for sample proportions and partial likeli-
hood ratio statistics for censored survival data. On the other hand, using an early response to treatment as a potential
surrogate endpoint for survival, Chen et al[9] proposed a joint model for binary response and a survival time for
clustered data, basing the statistical inference on a multivariate penalized likelihood method.
The design of clinical trials with survival endpoints taking into account previous information on binary endpoints
has received less attention. Abberbock et al[10] assessed how to relate the improvement in pCR with the effect size
in survival in the context of neoadjuvant breast cancer trials. In order to cope with the possibility of a non-constant
hazard ratio, Abberbock et al considered the average of the hazard ratio over the follow-up period as the effect measure.
Schoenfeld’s formula is then used to calculate the required number of events and augmented for the sample size under
the exponential distribution. However, as it has been widely discussed, both the hazard ratio and average hazard ratio
are difficult to interpret.[11, 12, 13, 14, 15] Furthermore, since the hazard ratio is sensitive to the length on which it is
computed,[16, 17] it can be difficult to anticipate in the design stage.
In this paper, we propose a design for clinical trials with long-term survival endpoints, given the information on
short-term binary endpoints. We distinguish between patients who respond to the binary endpoint, called responders,
and those who do not, called non-responders. The anticipated effect size and sample size are calculated on the basis
of the response rate of the binary endpoint, as well as on the survival functions for responders and non-responders in
each treatment arm. The corresponding survival distribution for each arm is hence a mixture between responders and
non-responders, and the common assumption on the proportionality of the hazard rates is unlikely to be satisfied. To
overcome these difficulties we propose to consider the restricted mean survival time for each treatment arm, and to
use their difference as the basis of comparison. The difference between the restricted mean survival times has several
advantages: it is easily interpretable as the mean difference in the survival times by the end of follow up,[13, 14] and
it does not require the proportionality of the hazards.
We present the effect size and sample size formulae for designing such trials. As shown in this work, the sample
size calculation requires previous knowledge on the survival by response distributions and the response rates for each
treatment group. We additionally outline how the sample size can be determined according to different parameter
choices. In order to make our proposal easy to use in practice, our method has been implemented in the survmixer
R package, which is publicly available.
This paper is organized as follows. In Section 2, we introduce the notation and main assumptions. In Section 3, we
describe the design of trials using restricted mean survival times and provide the effect size and sample size formulae
based on short-term endpoints and survival by response information. We present the R package survmixer in Section
4 and illustrate our proposal using a neoadjuvant trial in Section 5. We perform a simulation study in Section 6 to
2
evaluate the performance our proposal. We conclude the paper with a short discussion.
2. Notation and Assumptions
Consider a randomized clinical trial designed to compare two treatment groups, control group (i = 0) and in-
tervention group (i = 1), each composed of n(i) individuals, and denoting by n = n(0) + n(1) the total sample size.
Suppose that individuals from both groups are followed over the time interval [0,Tend] and are compared with respect
to a long-term time-to-event outcome evaluated within the interval [0, τ] (0 < τ ≤ Tend), such as event-free survival
(EFS). Let Ti j and Ci j be the time from randomization to the long-term outcome and to censoring, respectively, for
each subject j = 1, ..., n(i), i = 0, 1, and let S (i)(·) be the survival function of Ti j for the i-th group. Assume that Ti j and
Ci j are independent.
Assume that we have prior information on a short-term outcome, such as the pCR status.[3, 5] Based on this
short-term outcome, each patient who achieved the response is deemed a responder; otherwise, they are considered a
non-responder. Let Xi j = 1 indicate that the j-th patient in the i-th group is a responder; otherwise 0. Let p(i) be the
probability of having responded.
We aim to design a superiority phase III trial for a two-sample comparison between the control group and the
intervention group with respect to the long-term outcome as we establish in the following hypothesis:
H0 : S (0)(t) = S (1)(t), ∀t ∈ [0, τ] vs H1 : S (1)(t) ≥ S (0)(t), S (1)(t) > S (0)(t) for some t ∈ [0, τ]. (1)
2.1. Survival function and effect size in terms of the short-term outcome and responders
Let S (i)r (t) = P(Ti j > t|Xi j = 1) and S (i)nr(t) = P(Ti j > t|Xi j = 0) denote the survival functions for responders and
non-responders in the i-th group, respectively. The survival function for the long-term outcome in the i-th group can
then be expressed as a mixture of them as follows:
S (i)(t) = P(Ti j > t, Xi j = 1) + P(Ti j > t, Xi j = 0) = p(i) · S (i)r (t) + (1 − p(i)) · S (i)nr(t). (2)
From the survival function given in (2), the difference in survival functions at t (t ∈ [0, τ]) is as follows:
S (1)(t) − S (0)(t) = p(1)
(
S (1)r (t) − S (1)nr (t)
)
− p(0)
(
S (0)r (t) − S (0)nr (t)
)
+ S (1)nr (t) − S (0)nr (t).
Although the hazard ratio is the most commonly used effect measure in survival analysis, it relies on the assump-
tion of a constant hazard ratio over time between the two groups. However, under a mixture model such as (2), the
proportionality of the hazards rarely holds, even if the survival functions for responders and non-responders are expo-
nentially distributed,[10] as we will illustrate in Section 3.2.1. The expression of the hazard ratio under the mixture
model can be found in the Appendix (Theorem Appendix A.2).
As an alternative to the hazard ratio to quantify the effect of an intervention, we can use the difference of the
restricted mean survival times (RMSTs) for each group. The RMST is defined as the mean survival time within a
specific time window [0, τ], and it corresponds to the area under the survival curve until τ:
K(i)(τ) =
∫ τ
0
S (i)(t)dt. (3)
The RMST corresponding to the survival function given in (2) can be expressed as follows:
K(i)(τ) = p(i)K(i)r (τ) + (1 − p(i))K(i)nr (τ),
where K(i)r (τ) =
∫ τ
0 S
(i)
r (t)dt and K
(i)
nr (τ) =
∫ τ
0 S
(i)
nr(t)dt denote the RMST for the responders survival and the non-
responders survival in the i-th treatment arm, respectively. The difference between arms in RMSTs is then:
K(1)(τ) − K(0)(τ) =
(
p(1)K(1)r (τ) − p(0)K(0)r (τ)
)
+
(
(1 − p(1))K(1)nr (τ) − (1 − p(0))K(0)nr (τ)
)
, (4)
where each term in the above sum corresponds to a function of the responders and for non-responders survival func-
tions. Details for this derivation are provided in the Appendix (see Theorem Appendix A.1).
Note that if H0 in (1) is true, then K(1)(τ)−K(0)(τ) = 0; whereas, under H1, K(1)(τ)−K(0)(τ) > 0 and the hypothesis
can be equivalently stated as:
H0 : K(0)(τ) = K(1)(τ), ∀t ∈ [0, τ] vs H1 : K(1)(τ) > K(0)(τ). (5)
From now on and for the rest of the paper, we focus on H0 and H1 as stated in (5).
3
3. Sample Size based on short-term outcomes and survival-by-responders endpoints
In this section, we start describing the two-sample test based on the difference of the RMSTs. We then provide the
expression for the overall mean survival improvement and discuss different design settings. We end the section with
the derivation of the sample size based on the mixture survival function.
3.1. Test statistic
Let Sˆ (i)(·) be the Kaplan-Meier estimate of S (i)(·). A consistent estimator of the RMST in (3) is given by Kˆ(i)(τ) =∫ τ
0 Sˆ
(i)(t)dt. The distribution of
√
n(i) ·
(
Kˆ(i)(τ) − K(i)(τ)
)
is asymptotically normal with 0 mean and limiting variance(
σ(i)(τ)
)2
, defined as:
(
σ(i)(τ)
)2
= −
∫ τ
0
(K(i)(τ) − K(i)(t))2
(S (i)(t))2 ·G(i)(t) dS
(i)(t) = −
∫ τ
0
(
∫ τ
t S
(i)(u)du)2
(S (i)(t))2 ·G(i)(t)dS
(i)(t), (6)
where G(i)(·) is the survival function of the censoring variable Ci j for the i-th group.
To test the null hypothesis H0 in (5) against the alternative hypothesis H1, we consider the statistic:
Zs,n = (Kˆ(1)(τ) − Kˆ(0)(τ))
/√ (σˆ(0)(τ))2
n(0)
+
(σˆ(1)(τ))2
n(1)
, (7)
where σˆ(i)(τ) is the estimate of the variance
(
σ(i)(τ)
)2
, which is obtained by substituting K(i)(·), S (i)(·), and G(i)(·) by
its corresponding estimates Kˆ(i)(·), Sˆ (i)(·), and Gˆ(i)(·).
Let D(τ) = K(0)(τ) − K(1)(τ) be the minimum meaningful effect to be detected. Then, Dˆ(τ) = Kˆ(0)(τ) − Kˆ(1)(τ)
is a consistent estimator of D(τ). Moreover,
√
n
(
(Kˆ(0)(τ) − Kˆ(1)(τ)) − (K(0)(τ) − K(1)(τ))
)
is asymptotically normal
distributed with mean 0 and variance equal to (σ(0)(τ) + σ(1)(τ))2. By Slutsky’s theorem, the statistic Zs,n is asymp-
totically N(0, 1) under H0 and asymptotically normal with mean equal to D(τ)
/ √
((σ(0)(τ))2 + (σ(1)(τ)))2 and unit
variance under a fixed alternative equal to D(τ).
For further details on the restricted mean survival times, we refer to the work of Luo et al,[18] Zhao et al,[19] Pepe
and Fleming,[20] Gill,[21] and the references therein.
3.2. Effect size
We denote by ∆r(τ) = K
(1)
r (τ) − K(0)r (τ) and ∆nr(τ) = K(1)nr (τ) − K(0)nr (τ) the mean survival improvement of the
intervention group over the control group for responders and non-responders, respectively; and by ∆0(τ) = K
(0)
r (τ) −
K(0)nr (τ) the mean survival improvement of responders against non-responders in the control group. The treatment
effect on the response rate is denoted by δp = p(1) − p(0).
The overall mean survival improvement between treatment groups in (4) can be re-expressed as:
D(τ) = K(1)(τ) − K(0)(τ) = p(1) · ∆r + (1 − p(1)) · ∆nr + (p(1) − p(0)) · ∆0. (8)
Summarizing, the effect size D(τ) is then a function of the:
• ∆r = ∆r(τ): Mean survival improvement due to intervention among responders by time τ.
• ∆nr = ∆nr(τ): Mean survival improvement due to intervention among non-responders by time τ.
• ∆0 = ∆0(τ): Mean survival improvement of responders versus non-responders in the control group by time τ.
• δp: Improvement due to intervention on the response rate. Note that p(1) = p(0) + δp.
• p(0): Probability of response in the control group.
When designing a future phase III trial, we need to work closely with our medical collaborators to obtain these
quantities, which may be procured from ongoing or finished phase II trials (assessing similar agents) or historical data
using prior scientific knowledge.
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3.2.1. Effect size under different settings
Next, we discuss four different settings according to whether or not the survival functions between groups are the
same for responders and non-responders. We consider that the response rate of the intervention arm is higher than that
of the control arm (p(1) − p(0) > 0).
(I) S (1)r (t) = S
(0)
r (t), S
(1)
nr (t) = S
(0)
nr (t), S
(0)
r (t) > S
(0)
nr (t): The survival function for responders is expected to be
superior to that of non-responders. Hence, ∆r = K
(1)
r (τ) − K(0)r (τ) = 0, ∆nr = K(1)nr (τ) − K(0)nr (τ) = 0, ∆0 > 0, and
D(τ) = (p(1) − p(0)) · ∆0.
We note that, even in this simple scenario, the two overall survival functions, S (1)(·) and S (0)(·), are unlikely to
satisfy the proportional hazards assumption. Under the exponential case for both responders and non responders,
the overall survival distribution is no longer exponential:
S (i)(t) = p(i) · exp{−λ(i)r · t} + (1 − p(i)) · exp{−λ(i)nr · t},
where S (i)r (t) = exp{−λ(i)r · t} and S (i)nr(t) = exp{−λ(i)nr · t}. Moreover, the hazards ratio between two treatment
groups is then:
HR(t) =
p(0) · exp{−λ(0)r · t} + (1 − p(0)) · exp{−λ(0)nr · t}
p(1) · exp{−λ(1)r · t} + (1 − p(1)) · exp{−λ(1)nr · t}
· p
(1) · λ(1)r exp{−λ(1)r · t} + (1 − p(1)) · λ(1)nr exp{−λ(1)nr · t}
p(0) · λ(0)r exp{−λ(0)r · t} + (1 − p(0)) · λ(0)nr exp{−λ(0)nr · t}
,
showing that the hazard rates are not constant over time.
(II) S (1)r (t) = S
(0)
r (t), S
(1)
nr (t) > S
(0)
nr (t) (for t > τb): Survival improvement due to the intervention for non-responders,
but not for responders. This leads to ∆r = 0, ∆nr > 0, and hence:
D(τ) = (1 − p(1)) · ∆nr + (p(1) − p(0)) · ∆0.
(III) S (1)r (t) > S
(0)
r (t), S
(1)
nr (t) = S
(0)
nr (t) (for t > τb): Responders in the intervention group have longer survival than
control group responders, while there is no mean survival improvement among non-responders. Thus, we have
∆r > 0, ∆nr = 0, and then:
K(1)(τ) − K(0)(τ) = p(1) · ∆r + (p(1) − p(0)) · ∆0.
(IV) S (1)r (t) > S
(0)
r (t), S
(1)
nr (t) > S
(0)
nr (t) (for t > τb): Both responders and non-responders of the intervention group
have longer survival than those in the control group. Then ∆r > 0 and ∆nr > 0, so that the overall mean survival
improvement between groups is:
D(τ) = p(1) · ∆r + (1 − p(1)) · ∆nr + (p(1) − p(0)) · ∆0.
3.3. Sample size calculation
In order to compute the sample size to test (5) based on the statistic Zs,n, given in (7), we need information on
the following quantities: i) the responders rates p(0) and p(1) or, alternatively, instead of p(1), the effect given by
δp = p(1) − p(0)); ii) the responders and non-responders survival functions S (i)r (·) and S (i)nr(·), i = 0, 1; and iii) the
survival censoring function, G(i)(·).
Let n(p, S r, S nr,G) be the sample size needed for running a trial at significance level α with power 1 − β. Note
that the group indicator has been omitted in the notation for short. The formula for calculating the total sample size
n(p, S r, S nr,G) is given by:
n(p, S r, S nr,G) =
(zα + zβ)2
(D(τ))2
·
(
(σ(0)(τ))2
pi
+
(σ(1)(τ))2
1 − pi
)
, (9)
where pi = lim n(0)/n, zx is the 100× (1− x)-th percentile of the standard normal distribution, and the variance (σ(i)(τ))2
is:
(σ(i)(τ))2 = −p(i)
∫ τ
0
(
∫ τ
t (S
(i)
r (u)p(i) + S
(i)
nr(u)(1 − p(i)))du)2
(S (i)r (t)p(i) + S
(i)
nr(t)(1 − p(i)))2 ·G(i)(t)
dS (i)r (t)−(1−p(i))
∫ τ
0
(
∫ τ
t (S
(i)
r (u)p(i) + S
(i)
nr(u)(1 − p(i)))du)2
(S (i)r (t)p(i) + S
(i)
nr(t)(1 − p(i)))2 ·G(i)(t)
dS (i)nr(t).
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The derivation of the sample size (9) can be found in the Appendix (see Theorem Appendix A.3).
In order to evaluate D(τ), we can employ either (4), where the restricted mean survival times for responders
and non-responders are used, or (8), where the anticipated survival benefits for responders and non-responders are
considered. However, we notice that, if using (8) for anticipating D(τ) in n(p, S r, S nr,G), the anticipation of S
(i)
r (·)
and S (i)nr(·) in (σ(i)(τ))2 has to be in consonance with the expected effect sizes (∆r,∆nr,∆0).
3.3.1. Sample size based on interpretable parameters
The prior information needed to compute the sample size might be in terms of different summary statistics. In
this section, we propose three distinct sets of summaries; choosing one or another would depend on the previous in-
formation on the survival functions for responders and non-responders. These three summary statistics are essentially
equivalent under our distributional assumptions.
In this section, we assume that both responders and non-responders survival functions follow exponential distri-
butions. Similar derivations, if Weibull distributions are assumed, can be found in the supplementary material. The
censoring distribution is assumed to be exponential.
Researchers should have the response rate in the control group, p(0), the anticipated effect due to the intervention
in the response rate, δp, and the scale parameter for the censoring distribution. Furthermore, one of the following three
sets of summaries are needed:
• Summary statistics (I): Sample size based on (m(0)r , m
(0)
nr , m
(1)
r − m(0)r , m(1)nr − m(0)nr ):
We would need the mean survival time for responders and non-responders distributions in the control group,
m(0)r and m
(0)
nr , and the differences in mean survival time for responders and non-responders, m
(1)
r − m(0)r and
m(1)nr − m(0)nr , respectively.
From there, we could directly translate these anticipated values to the parameters of the exponential distributions
and calculate the sample size accordingly using (9).
• Summary statistics (II): Sample size based on (S (1)r (τ) − S (0)r (τ), S (1)nr (τ) − S (0)nr (τ), S (0)r (τ), S (0)nr (τ)):
We would require here the τ-year survival rates for responders and non-responders in the control group, S (0)r (τ)
and S (0)nr (τ), and the difference in survival functions at τ for responders and non-responders, S
(1)
r (τ)−S (0)r (τ) and
S (1)nr (τ) − S (0)nr (τ).
Based on this information, we could deduce the parameters of the exponential distributions and calculate the
sample size according to 9.
• Summary statistics (III): Sample size based on (S (0)r (τ), S
(0)
nr (τ), ∆r,∆nr):
We would need the τ-year survival rates for responders and non-responders in the control group, S (0)r (τ) and
S (0)nr (τ), and the mean survival improvement for responders and non-responders, ∆r and ∆nr.
Based on this information, we establish the underlying relationships between the anticipated set of parameters
and the parameters of the exponential distribution and get approximated values for the rate parameters using the
Taylor series. Once we have the parameters, we calculate the sample size according to 9.
In the supplementary material, we stated the formulae that we have used to obtain the distributional parameters
from each of the summary statistics.
4. Implementation
Results in Section 3 allow for the calculation of the sample size and effect size for overall survival based on the
response rate and the survival-by-response information. To make these results accessible to clinical trial practition-
ers, we have created the R package survmixer (https://github.com/MartaBofillRoig/survmixer), which
incorporates two main functions: survm effectsize and survm samplesize for calculating the effect size (RMST
difference) in (8) and the sample size in (9), respectively.
In the function survm effectsize, the RMST difference can be computed based on two different sets of argu-
ments, the choice of which is based on the parameter anticipated effects. If anticipated effects is TRUE,
the overall mean survival improvement is computed based on the formula (8), and then using the set of arguments
(∆r,∆nr, ∆0, p(0), δp), that is:
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survm_effectsize(Delta_r,Delta_0,Delta_nr ,delta_p,p0 , anticipated_effects=TRUE)
where Delta r, Delta 0, Delta nr, delta p, p0 are the already introduced parameters ∆r, ∆nr, ∆0, ∆p and
p(0).
On the other hand, if anticipated effects is FALSE, the overall mean survival improvement is computed
according to (4) and then based on the set of arguments (S (0)r (·), S (1)r (·), S (0)nr (·), S (1)nr (·), p(0), δp), that is:
survm_effectsize(ascale0_r, ascale0_nr , ascale1_r, ascale1_nr , delta_p, p0 ,
bshape0=1, bshape1=1, tau , anticipated_effects=FALSE)
where delta p, p0 are the effect size and event rate for the response rate (δp, p(0)); ascale0 r,ascale0 nr,
ascale1 r,ascale1 nr are the scale parameters for the distribution in both the control and intervention groups
for responders and non-responders; and tau is the end of follow up. The responders and non-responders survival
functions are assumed to be exponentially distributed. However, they can be assumed to be Weibull distributed by
using the arguments bshape0,bshape1, which are the shape parameters in the control and intervention groups.
The survm samplesize function computes the sample size on the basis of different sets of summary statistics, as
explained in Section 3.3.1. The user can choose which set of summaries to use by means of the argument set param.
This function can be called for each of the parameter settings by:
survm_samplesize(m0_r,m0_nr ,diffm_r,diffm_nr ,delta_p,p0 ,tau ,ascale_cens ,
alpha ,beta ,set_param =1)
survm_samplesize(S0_r,S0_nr ,diffS_r,diffS_nr ,delta_p,p0 ,tau ,ascale_cens ,
alpha ,beta ,set_param =2)
survm_samplesize(Delta_r,Delta_nr ,S0_r,S0_nr ,delta_p,p0 ,tau ,ascale_cens ,
alpha ,beta ,set_param =3)
where the arguments:
• m0 r, m0 nr are the mean survival time for responders and non-responders in the control group (m(0)r ,m
(0)
nr );
• diffm r, diffm nr are the difference in mean survival time between group for responders and non-responders
(m(1)r − m(0)r , m(1)nr − m(0)nr );
• S0 r, S0 nr are the τ-year survival rates for responders and non-responders in the control group (S (0)r (τ),
S (0)nr (τ));
• diffS r, diffS nr are the difference in survival functions at τ for responders and non-responders (S (1)r (τ) −
S (0)r (τ), S
(1)
nr (τ) − S (0)nr (τ));
• Delta r, Delta nr, delta p, p0 are the same arguments that we have in survm effectsize (∆r,∆nr,
δp, p(0));
• ascale cens is the scale parameter for the censoring distribution;
• alpha and beta are the pre-specified type I and type II errors, respectively.
5. Motivating Example: The NOAH trial
In phase III of the NOAH (NeOAdjuvant Herceptin) trial,[22, 23] the primary objective was to assess whether
neoadjuvant chemotherapy with one year of trastuzumab improved event-free survival as compared with neoadjuvant
chemotherapy alone in patients with HER2-positive breast cancer. Patients in the NOAH trial were randomly assigned
to receive neoadjuvant chemotherapy alone or neoadjuvant chemotherapy plus one year of trastuzumab. The primary
endpoint was event-free survival, defined as the time from randomization until disease recurrence, progression, or
death from any cause. Secondary endpoints were, among others, pathological complete response (pCR) in breast
tissue and overall survival.
A total of 235 patients with HER2-positive disease were enrolled in the study, of whom 118 received chemotherapy
alone and 117 received chemotherapy plus trastuzumab. The sample size was calculated using Shoenfeld’s formula
to have 80% power to detect a hazard ratio of 0.545 on the primary endpoint at a two-sided α level of 0.05, assuming
a median event-free survival of 5.5 years with trastuzumab plus chemotherapy. The two treatment groups were com-
pared using the logrank test, and a Cox proportional hazards model was used to estimate the hazard ratios and to test
their significance.
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For illustrative purposes, we assume that a phase III trial is to be conducted based on the estimated values of the
pCR rate in each treatment arm, and 5-year survival rate by pCR status in each treatment arm observed from the NOAH
trial. The NOAH trial showed that the overall event-free survival at 5 years was 58% (87% for pCR responders and
38% for non-responders) in the trastuzumab plus chemotherapy group (trastuzumab group for short), and it was 43%
in the neoadjuvant chemotherapy group (55% for pCR responders and 41% for non-responders); whereas the pCR
rate was 0.38 in the trastuzumab group and 0.19 in the chemotherapy group. Based on these results as model inputs
and assuming exponential distributions for the survival and censoring distributions, the mean event-free survival value
is 8.36 and 5.61 years for responders and non-responders in the chemotherapy group, respectively, and 35.90 and 5.17
years for responders and non-responders in the trastuzumab group, respectively.
Observe that non-responders in the chemotherapy group have slightly larger survival than the non-responders in the
trastuzumab group. For the purpose of clarity, we assume for the illustration that both responders and non-responders
follow the same survival function with the mean equals to 5.17 years. We additionally assume equal exponential
censoring distributions for the two groups with the mean equals to 7 years.
Table 1 provides the values we are using to compute the sample size in this hypothetical new study. Figure 1 shows
the survival functions by response for each treatment arm, as well as the survival functions for the whole population
calculated as the mixture of responders and non-responders given in (2). Figure 1 also plots the hazard ratio between
treatment arms over time (given in (A.3)); observe that it lies between 0.45 to 0.65. This departure from constancy is
the consequence of the different survival patterns of pCR responders and non-responders within the survival mixture
model.
Table 1: Anticipated parameters for the design of the phase III trial: Probability of the binary endpont pCR in each treatment group (p(0) and
p(1)); 5-year survival rates for responders and non-responders in each treatment group, S (i)r (τ) and S
(i)
nr (τ), i = 0, 1; and the mean survival time for
the exponential functions by treatment arm, by pCR response, and for the censoring distribution.
Parameters Anticipated values
Probability of achieving pCR in chemotherapy group 0.19
in trastuzumab group 0.38
5-year survival rate for responders in trastuzumab group 0.87
for responders in chemotherapy group 0.38
for non-responders in trastuzumab group 0.41
for non-responders in chemotherapy group 0.41
Mean survival time for responders in trastuzumab group 35.90
for responders in chemotherapy group 8.36
for non-responders in trastuzumab group 5.61
for non-responders in chemotherapy group 5.61
for censoring 7
We guide the reader on how to get the expected overall mean survival improvement and how to size the phase III
trial using the survmixer package (in Section 4). We calculate the overall mean survival improvement (RMST differ-
ence) between groups by means of the function survw effectsize. To do so, we consider the values of the mean sur-
vival time for responders and non-responders in each group, the probability of achieving pCR response in the control
group, and the response difference between groups (see Table 1). As shown below, the function survw effectsize
returns the overall mean survival improvement and the mean survival improvement that would be assumed for both
responders and non-responders.
survm_effectsize(ascale0_r=8.37 , ascale0_nr=5.61 , ascale1_r=35.90 , ascale1_nr=5.61 ,
delta_p=0.19 ,p0=0.19 ,tau=5)
## Parameter Value
## 1 RMST difference 0.43
## 2 RMST difference responders 0.90
## 3 RMST difference non -responders 0.00
## 4 Response difference 0.19
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Figure 1: The top-left plot depicts the survival functions for event-free survival for each treatment arm (S (0)(·) and S (1)(·)), calculated by means
of (2) and using the values in Table 1. The top-right plot is the hazard ratio over the follow-up period (calculated using (A.3)). The bottom-left
and bottom-right plots are the survival functions by response in each treatment arm (S (0)r (·) and S (1)r (·) for responders, and S (0)nr (·) and S (1)nr (·) for
non-responders).
The resulting overall mean survival improvement of trastuzumab over neoadjuvant chemotherapy is 0.43 years. This
difference is mainly because of the mean survival improvement among responders, since the mean survival improve-
ment between groups (∆r) in the patients that responded is 0.90 years, whereas there is no improvement for non-
responders, ∆nr = 0.
Using the difference in survival functions between groups at τ = 5 for both responders and non-responders, the
probability of response in the control group, and the improvement on the response rate, we calculate the sample size
to have 80% power to detect a difference in event-free survival between the two treatment arms over 5 years of follow
up. We employ the survw samplesize function to compute the sample size according to (9), obtaining that a total
sample size of 466 is needed.
survm_samplesize(S0_r=0.55 ,S0_nr=0.41 , diffS_r=0.32 , diffS_nr=0,p0=0.19 , delta_p
=0.19 ,
ascale_cens=7,tau=5,alpha =0.05, beta =0.2,set_param =2)
## Parameter Value
## 1 Sample size 465.98
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## 2 RMST difference 0.43
We performed a simulation study to compare the statistical power of the NOAH trial and the one we proposed
using the parameter inputs derived from the NOAH trial. We assumed exponential distributions for the survival
functions for each of the four subgroups, considered the parameters in Table 1, and replicated 10000 times to estimate
the power to detect a statistically significant difference in event-free survival between the two arms. When simulating
trials of size n = 235, as in the NOAH trial, we obtained an empirical power of 0.33 using the log-rank test and an
empirical power of 0.41 using the RMST test (in (7)) to detect an improvement in event-free survival of trastuzumab
plus chemotherapy over chemotherapy alone. On the other hand, when using trials of size n = 466, we obtained an
empirical power of 0.76 using the log-rank test and an empirical power of 0.80 using the RMST test. Note that in both
situations our approach leads to higher powers. We have additionally evaluated the empirical power under various
censoring percentages. The results (not included) show that the empirical powers using the RMST test were, all of
them, around 0.80 and higher than the ones using the log-rank test.
6. Simulation Study
6.1. Design
In this section, we conduct additional simulation studies to evaluate the performance of the proposed sample size
calculation in terms of the significance level and the power. We simulated a short-term binary endpoint according
to the probability of responding to the treatment in control arm p(0) and a difference in response rate between arms
of δp = p(1) − p(0). For the time-to-event endpoint, we generated the survival times from Weibull distributions for
the responders and non-responders survival distributions with scale parameters a(i)r and a
(i)
nr , respectively, and common
shape parameter b; that is:
S (i)r = exp{−(t/a(i)r )b} and S (i)nr = exp{−(t/a(i)nr)b}. (10)
The censoring distributions were assumed equal between groups and exponential with scale parameter acens = 2 ·m(0)nr ,
where m(0)nr is the mean of the non-responders in group 0, that is, m
(i)
nr = a
(i)
nr · Γ(1 + 1/b). The same assumption was
made in Hatzis et al.[6]
The parameter values used for the simulations are found in Table 2. We have only considered scenarios that
produce realistic situations and, in particular, that satisfy that ∆r ≥ 0, ∆nr ≥ 0, and ∆0 ≥ 0. The set of scenarios
we considered is available in the GitHub repository survmixer. For each one of these scenarios, we computed the
required sample size using (9) for a one-sided test with power 1 − β = 0.80 at significance level α = 0.05. Only those
scenarios that result in sample sizes between 100 and 5000 were taken into account. The total number of scenarios
considered was 144.
We performed 1000 replications for each configuration and evaluated the power and the significance level by using
the RMST test in (7). For comparison purposes, we also present the results using the log-rank test.
6.2. Results
The results yield to RMST differences for the overall survival between 0.15 and 1.82, with median 0.60; and to
sample sizes between 125 and 4824, with median 685. Figure 1 in the supplementary material summarizes the sample
sizes and effect sizes obtained for the overall survival under the considered scenarios with respect to the settings I
to IV discussed in Section 3.2.1. We notice that the scenarios corresponding to settings I and III are the ones with
smaller effect sizes, thus requiring larger sample sizes to achieve the same power.
Figure 2 shows boxplots of the empirical power and the significance level when using the RMST test and the
logrank test using the same sample sizes. We notice that the power obtained using the RMST test is centered around
0.80, and it has a small variability. When comparing with the results using the log-rank test, we observe that the power
using the log-rank test is in general less than 0.80, and there is a greater variability as compared with the results using
the RMST test. The empirical significance level is close to the type I error 0.05 using both tests.
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Table 2: Simulation scenarios. When simulating under the null hypothesis, we have considered that a(1)nr = a
(0)
nr , a
(1)
r = a
(0)
r , and δp = 0. When
simulating under the alternative hypothesis, we have not considered all possible combinations, we restricted our calculations to those scenarios that
yield ∆r ≥ 0, ∆nr ≥ 0, and ∆0 ≥ 0, and whose resulting sample sizes are between 100 and 5000.
Parameters Values
τ 10
p(0) 0.1, 0.3
b 1, 2
a(0)r 15, 18, 20, 22, 50
a(0)nr 5, 6, 7, 8, 9, 10, 11, 15, 17, 29
Under the null hypothesis a(1)nr = a
(0)
nr
a(1)r = a
(0)
r
δp 0
Under the alternative hypothesis a(1)nr 5, 7, 8, 9, 10, 11, 13, 15, 17, 19, 20, 29, 35, 40
a(1)r 22, 25, 50, 55, 62, 65
δp 0.1, 0.3
α 0.05
β 0.2
7. Discussion
Pathologic complete response (pCR) is a common primary endpoint for a phase II trial or for accelerated approval
of neoadjuvant cancer therapy. If granted, the regulatory agencies FDA[1] and EMA[2] require a two-arm confirma-
tory trial to demonstrate the efficacy with a long-term survival outcome, such as overall survival. Because there is not
direct way to relate the effects on pCR with the effects on the survival endpoint, sample size calculation relying on
anticipated values for OS is not straightforward. In this work, we have approached how to size trials for a survival
endpoint based on previous information on a short-term binary endpoint such as pCR. Our proposal is built on the
mixture distribution between the binary response and the survival by response and uses the difference of restricted
mean survival times (RMSTs) as the effect measure to compare the two treatment arms. We show that both the sample
size and the effect size can be written in terms of the probability of response of each treatment arm, and the respon-
ders and non-responders survival functions. The proposed design is suitable for the designing of long-term phase III
neoadjuvant trials given short-term binary outcomes, since, among other reasons, it does not rely on the proportional
hazard assumption.
In recent years, the difference between RMSTs has arisen as an alternative measure for the treatment effect instead
of the hazard ratios when the proportional hazards assumption is in doubt.[13, 14] Although the RMSTs and their
variances can be estimated from data, in the planning stage, their computation involves numerical integrals whose
analytic solutions are usually hard to obtain, which makes it difficult to calculate the sample size. In this work,
we have proposed sample size calculations for planning the trial using RMSTs based on interpretable parameters
without resorting to simulation. These calculations provide an explicit solution to compute the sample size under the
assumption that the survival function of both responders and non-responders follows a commonly used parametric
distribution such as exponential or Weibull. All the necessary sample size calculations have been implemented in the
R package survmixer. The proposed sample size formulae, based on asymptotic results for the RMST difference,
are intended to be used in phase III trials where the sample size is expected to be modest or large.
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Appendix A. Derivations of the survival functions based on the mixture model
For the i-th group (i = 0, 1), and for each subject j = 1, ..., n(i), let Ti j and Ci j be the time from randomization to the
long-term survival outcome and to censoring, respectively, and assume that Ti j and Ci j are independent. Let Xi j = 1
indicate that the j-th patient is a responder and Xi j = 0, otherwise, and let p(i) be the probability of having responded.
Let S (i)(·) be the survival function of Ti j, and S (i)r (·) and S (i)nr(·) denote the responders survival and non-responders
survival functions. Let K(i)r (τ) =
∫ τ
0 S
(i)
r (t)dt and K
(i)
nr (τ) =
∫ τ
0 S
(i)
nr(t)dt be the restricted mean survival times at τ for
responders and non-responders in the i-th group, respectively.
Theorem Appendix A.1. The long-term survival function, S (i)(·), can be expressed in terms of the response probabil-
ity, p(i), and the survival functions for responders and for non-responders, S (i)r (t) and S
(i)
nr(t), respectively, as follows:
S (i)(t) = p(i) · S (i)r (t) + (1 − p(i)) · S (i)nr(t), (A.1)
and the restricted mean survival times is given by:
K(i)(τ) = p(i)K(i)r (τ) + (1 − p(i))K(i)nr (τ). (A.2)
Proof. By definition of the responders and non-responders survival functions, S (i)r (t) = P(Ti j > t|Xi j = 1) and
S (i)nr(t) = P(Ti j > t|Xi j = 0). Therefore we have that:
S (i)(t) = P(Ti j > t, Xi j = 1) + P(Ti j > t, Xi j = 0) = p(i) · S (i)r (t) + (1 − p(i)) · S (i)nr(t),
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and hence:
K(i)(τ) =
∫ τ
0
S (i)r (t)p
(i) + S (i)nr(t)(1 − p(i))dt = p(i)
∫ τ
0
S (i)r (t)dt + (1 − p(i))
∫ τ
0
S (i)nr(t)dt,
which is the same expression that in (A.2). 
Theorem Appendix A.2. Treatment effects between groups for the long-term survival outcome in terms of the dif-
ference in t-year survival rates, difference in restricted mean survival times or hazard ratio are functions in terms of
the probabilities of being responder, p(0) and p(1), and the survival-by-response functions S (0)r (t), S
(1)
r (t), S
(0)
nr (t) and
S (1)nr (t), as follows:
(i) The difference in t-year survival rates is given by:
S (1)(t) − S (0)(t) = p(1)
(
S (1)r (t) − S (1)nr (t)
)
− p(0)
(
S (0)r (t) − S (0)nr (t)
)
+ S (1)nr (t) − S (0)nr (t).
(ii) The difference between the restricted mean survival times is as follows:
K(1)(τ) − K(0)(τ) =
(
p(1)K(1)r (τ) − p(0)K(0)r (τ)
)
+
(
(1 − p(1))K(1)nr (τ) − (1 − p(0))K(0)nr (τ)
)
.
(iii) The hazard ratio has the following expression:
HR(t) =
p(0) · S (0)r (t) + (1 − p(0)) · S (0)nr (t)
p(1) · S (1)r (t) + (1 − p(1)) · S (1)nr (t)
· p
(1) · f (1)r (t) + (1 − p(1)) · f (1)nr (t)
p(0) · f (0)r (t) + (1 − p(0)) · f (0)nr (t)
, (A.3)
where f (i)r (·) and f (i)nr (·) denote the density functions for responders and non-responders in the i-th group, re-
spectively.
Proof. The proofs of (i) and (ii) follow from Theorem Appendix A.1. To see (iii), first notice that:
HR(t) =
−d ln[S (1)(t)]/dt
−d ln[S (0)(t)]/dt
then, if we replace S (i)(t) (i = 0, 1) by its expression in (A.1), we have:
HR(t) =
−d ln[S (1)(t)]/dt
−d ln[S (0)(t)]/dt =
−d ln[p(1) · S (1)r (t) + (1 − p(1)) · S (1)nr (t)]/dt
−d ln[p(0) · S (0)r (t) + (1 − p(0)) · S (0)nr (t)]/dt
=
p(0) · S (0)r (t) + (1 − p(0)) · S (0)nr (t)
p(1) · S (1)r (t) + (1 − p(1)) · S (1)nr (t)
· p
(1) · f (1)r (t) + (1 − p(1)) · f (1)nr (t)
p(0) · f (0)r (t) + (1 − p(0)) · f (0)nr (t)
=
S (0)(t)
S (1)(t)
· p
(1) · f (1)r (t) + (1 − p(1)) · f (1)nr (t)
p(0) · f (0)r (t) + (1 − p(0)) · f (0)nr (t)
.
Finally, the expression in (A.3) is obtained by substituting S (0)(t) and S (1)(t) with their expressions in terms of the
response probability and survival-by-response functions in (A.1). 
Theorem Appendix A.3. Considering the hypothesis problem given in 1, that is,
H0 : S (0)(t) = S (1)(t), ∀t ∈ [0, τ] vs H1 : S (1)(t) ≥ S (0)(t), S (1)(t) > S (0)(t) for some t ∈ [0, τ],
and the statistic Zs,n in (7),
Zs,n = (Kˆ(1)(τ) − Kˆ(0)(τ))
/√ (σˆ(0)(τ))2
n(0)
+
(σˆ(1)(τ))2
n(1)
,
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the sample size n(p, S r, S nr,G) needed for running a trial at one-sided significance level α with power 1 − β, is given
by:
n(p, S r, S nr,G) =
(zα + zβ)2((
p(1)K(1)r (τ) − p(0)K(0)r (τ)
)
+
(
(1 − p(1))K(1)nr (τ) − (1 − p(0))K(0)nr (τ)
))2 · ( (σ(0)(τ))2pi + (σ(1)(τ))21 − pi
)
,
(A.4)
where pi = lim n(0)/n, and zx is the 100 × (1 − x)-th percentile of the standard normal distribution; and where the
variance (σ(i)(τ))2 is:
(σ(i)(τ))2 = −p(i)
∫ τ
0
(
∫ τ
t (S
(i)
r (u)p(i) + S
(i)
nr(u)(1 − p(i)))du)2
(S (i)r (t)p(i) + S
(i)
nr(t)(1 − p(i)))2 ·G(i)(t)
dS (i)r (t)−(1−p(i))
∫ τ
0
(
∫ τ
t (S
(i)
r (u)p(i) + S
(i)
nr(u)(1 − p(i)))du)2
(S (i)r (t)p(i) + S
(i)
nr(t)(1 − p(i)))2 ·G(i)(t)
dS (i)nr(t).
Proof. The required sample size n(p, S r, S nr,G) needs to satisfy the following equation:
K(0)(τ) − K(1)(τ)√
(σ(0)(τ))2
n(0) +
(σ(1)(τ))2
n(1)
= zα + zβ
and hence:
n =
(zα + zβ)2
(D(τ))2
·
(
(σ(0)(τ))2
pi
+
(σ(1)(τ))2
1 − pi
)
, (A.5)
where σ(i) is given in (6). Taking into account that the overall mean survival improvement can be written as:
D(τ) =
(
p(1)K(1)r (τ) − p(0)K(0)r (τ)
)
+
(
(1 − p(1))K(1)nr (τ) − (1 − p(0))K(0)nr (τ)
)
,
then the expression of n(p, S r, S nr,G) in (A.4) is obtained substituting the survival function S (i)(·) in σ(i) by the
survival mixture given in (2) into the formula (A.5). 
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